Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Breast Cancer ; 17(5): 382-391, 2017 08.
Article in English | MEDLINE | ID: mdl-28529029

ABSTRACT

BACKGROUND: We aimed to describe our experience with metaplastic breast carcinoma (MBC), evaluate its clinical outcome compared with triple-negative breast cancer (TNBC), and provide a through and comprehensive review of the literature to date. MATERIALS AND METHODS: We reviewed MBC cases (n = 46) from our institution. The following variables were recorded: tumor histologic subtype, Nottingham grade, tumor size, lymph node status, Tumor, Node, Metastases stage, biomarkers profile, patient's age and race, therapy modality (chemotherapy and radiation), and survival (disease-free survival [DFS] and overall survival [OS]). The clinical and pathological data for TNBC (n = 508) cases were extracted from the breast cancer database. To compare the survival between MBC and TNBC, a subgroup of MBC cases (n = 40) were matched with TNBC cases (n = 40) on the basis of known prognostic confounders. RESULTS: There were 17 of 46 (37%) cases with mesenchymal differentiation, 12 (26.1%) squamous cell carcinoma, 14 (30.4%) spindle cell carcinoma, and 3 (6.5%) mixed type. MBC presented at a more advanced stage than TNBC (P = .014) and was more likely to recur (34% vs. 15.5%; P = .004). More MBC patients died from disease than TNBC (29% vs. 16%; P = .05). In the multivariate analysis, MBC had approximately twice the risk of local recurrence than TNBC (95% confidence interval, 1.01-3.83; P = .05). MBC patients had worse DFS and OS than the matched TNBC patients (P < .001 and P = .033, respectively). A review of the literature comparing MBC versus TNBC is presented. CONCLUSION: Our results suggest that MBC is clinically more aggressive than TNBC. Further studies might help delineate the differences between these 2 entities.


Subject(s)
Carcinoma, Ductal, Breast/pathology , Carcinoma, Squamous Cell/pathology , Metaplasia/pathology , Neoplasm Recurrence, Local/pathology , Triple Negative Breast Neoplasms/pathology , Adult , Aged , Biomarkers, Tumor/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Ductal, Breast/therapy , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/therapy , Female , Humans , Metaplasia/metabolism , Metaplasia/therapy , Middle Aged , Neoplasm Recurrence, Local/metabolism , Neoplasm Recurrence, Local/therapy , Prognosis , Survival Rate , Triple Negative Breast Neoplasms/metabolism , Triple Negative Breast Neoplasms/therapy
2.
Anticancer Res ; 35(5): 2857-60, 2015 May.
Article in English | MEDLINE | ID: mdl-25964567

ABSTRACT

BACKGROUND: Chondrosarcoma of the bladder is an extremely rare disease. Only five previously described cases are known in the medical literature. PATIENTS AND METHODS: We present a chondrosarcoma developed 19 years after radiation treatment in a 73-year-old patient. A literature search of articles published from 1984 to 2014 was performed. RESULTS: This is the first reported case of post-radiation bladder chondrosarcoma. We compared the clinicopathological features of the previously reported cases and reviewed the medical literature of the bladder sarcomas and post-radiation sarcomas. CONCLUSION: The primary treatment for bladder mesenchymal neoplasms is surgical, preferably radical cystectomy with or without chemotherapy. Positive surgical margin is one of the most important factors negatively affecting disease-specific, recurrence-free and overall survival rates.


Subject(s)
Chondrosarcoma/pathology , Neoplasms, Radiation-Induced/pathology , Urinary Bladder Neoplasms/pathology , Aged , Chondrosarcoma/drug therapy , Chondrosarcoma/radiotherapy , Female , Humans , Neoplasms, Radiation-Induced/drug therapy , Neoplasms, Radiation-Induced/radiotherapy , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/radiotherapy
SELECTION OF CITATIONS
SEARCH DETAIL
...